Update on the aducanumab (Aduhelm) saga, retirement, financial advice, cognitive health, excessive worrying, neurotech, and more

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, pro­vid­ing this time a sum­ma­ry of the saga around the FDA approval of adu­canum­ab (Aduhelm) as a sup­posed treat­ment for Alzheimer’s Dis­ease, plus a range of time­ly research find­ings and resources for life­long brain health. First, below are some key reads to nav­i­gate “prob­a­bly the worst drug approval…

Read More

First, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all

6 ways the FDA’s approval of Aduhelm does more harm than good (STAT News): Like many peo­ple, I was shocked when the Food and Drug Admin­is­tra­tion ignored the advice of its neu­ro­log­i­cal drugs advi­so­ry pan­el and broad­ly approved Biogen’s new drug, Aduhelm, even for pop­u­la­tions nev­er includ­ed in the clin­i­cal tri­als to assess the drug.

Read More

Study in China finds that retirement may accelerate cognitive decline, even for those with stable income

Peo­ple who retire ear­ly suf­fer from accel­er­at­ed cog­ni­tive decline and may even encounter ear­ly onset of demen­tia, accord­ing to a new eco­nom­ic study (Note: opens PDF) I con­duct­ed with my doc­tor­al stu­dent Alan Adel­man. To estab­lish that find­ing, we exam­ined the effects of a rur­al pen­sion pro­gram Chi­na intro­duced in 2009 that pro­vid­ed peo­ple who…

Read More

Don’t worry, be happy: How excessive worrying may influence the rate of neurodegeneration

Wor­ry­ing and the Aging Brain (Dana Foun­da­tion): Over the past decade, sci­en­tists and clin­i­cians have not­ed a sig­nif­i­cant asso­ci­a­tion between com­mon men­tal health con­di­tions and accel­er­at­ed brain aging—the changes to brain struc­ture, phys­i­ol­o­gy, and func­tion that are thought to lead to lat­er cog­ni­tive decline. Both depres­sion and anx­i­ety dis­or­ders, for exam­ple, are strong­ly cor­re­lat­ed with…

Read More

On building better brains at any age, treating Depression vs. Dementia, emerging neurotechnologies, psychedelics, and more

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eleven new research find­ings and inno­v­a­tive resources for life­long cog­ni­tive and brain health. #1. Debate: Are depres­sion and demen­tia two sides of the same coin? And, if they are, how to best approach treat­ment? #2. Either way, the ear­li­er the bet­ter, but it’s nev­er too late: New…

Read More

Debate: Are depression and dementia two sides of the same coin? And, if they are, how to best approach treatment?

Every sev­en sec­onds, some­one in the world is diag­nosed with demen­tia. A typ­i­cal case that I often see in my prac­tice is as fol­lows: A 76-year-old woman has a two-year his­to­ry of pro­gres­sive wors­en­ing of short-term mem­o­ry and cog­ni­tive decline. She can’t recall the names of her grand­chil­dren and is dev­as­tat­ed by her dete­ri­o­rat­ing abilities.…

Read More